Adult Vaccine 2013 final
-
Upload
ahmed-saad -
Category
Education
-
view
206 -
download
2
description
Transcript of Adult Vaccine 2013 final
![Page 1: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/1.jpg)
![Page 2: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/2.jpg)
ADULT IMMUNIZATIONupdate 2013
Ahmed Saad MD. FACP.Assistant Prof Internal Medicine &
Infectious Diseases Cairo university
![Page 3: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/3.jpg)
DisclosuresI have no financial conflict or interest with
the manufacturer of any product named during this presentation .
I will not discuss vaccines not licensed by the FDA
![Page 4: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/4.jpg)
2013 Vaccine Updates
Influenza
Pneumococcal
Herpes Zoster
T dap
HPV
Meningococcal
Hepatitis Vaccine
Varicella
![Page 5: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/5.jpg)
When dealing with a disease, I never think of finding a remedy for it, but, instead, a means of prevention
Louis Pasteur (1822-1895) A Vision to future of humanity
![Page 6: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/6.jpg)
Why adult vaccinations?
Adult deaths from vaccine preventable diseases =
60,000
From: IOM, Calling the Shots: Immunization Finance Policies and Practices, 2000.
![Page 7: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/7.jpg)
Some adults incorrectly assume that the vaccines they received as children will protect them for the rest of their lives.
Some adults were never vaccinated as children
Newer vaccines were not available when some adults were children
Immunity can begin to fade over time As we age, we become more susceptible to
serious disease caused by common infections (e.g., flu, pneumococcus)
Why some adults need vaccines?
![Page 8: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/8.jpg)
Burden of Adult Vaccine-Preventable Disease
Influenza: 10-20% of US people annually
36,000 deaths (average)Pertussis: 1 millionCervical cancer: 10,000H Zoster : 1 millionPneumococcal: 2,000-5000 meningitis 40,000 bloodstream
infections 150,000-300,000
pneumonia
![Page 9: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/9.jpg)
Incidence rates for invasive PD (IPD) in the Middle East
1. Garcia CR et al. Poster presented at 8th bi-annual International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD8), Iguacu Falls, Brazil (March, 2012).
![Page 10: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/10.jpg)
The conjugation of a polysaccharide to a carrier protein leads to the interaction with T cells resulting in the release of functional antibodies and production of memory B cells 1,2
T-independent
Plasma cell
B cell
Presentation
B cellT cell
Memory B cell T-dependent
Plasma cell
What makes a conjugate different?
Polysaccharide antigens
+ =
carrier protein Conjugate vaccine
1. de Roux A et al. Clin Infect Dis. 2008;46:1015-1023. 2. Pollard AJ et al. Nat Rev Immunol. 2009;9:213-220.
![Page 11: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/11.jpg)
Each year, the Advisory Committee on Immunization Practices (ACIP) reviews the recommended adult immunization schedule to ensure that the schedule reflects current recommendations for the licensed vaccines.
Recommended Adult Immunization Schedule — United States, 2013
![Page 12: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/12.jpg)
From: http://www.cdc.gov/vaccines/recs/schedules/adult-schedule.htm
![Page 13: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/13.jpg)
![Page 14: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/14.jpg)
Influenza Vaccine
![Page 15: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/15.jpg)
Influenza VirusFamily
Orthomyxoviridae
Three main typesType A
Multiple speciesType B
HumansType C
Humans and swine
![Page 16: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/16.jpg)
Influenza updates For the (Live Attenuated Influenza
Vaccine) LAIV, beginning with 2013–14 season, only the quadrivalent formulation will be available and trivalent formulation will stop.
It contains 2 influenza A (H3N2) and (H1N1),
plus 2 influenza B vaccine virus strains Also the name inactivate influenza
vaccine( IIV ) replaced the name trivalent inactivated vaccine ( TIV)
![Page 17: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/17.jpg)
Influenza updates Annual vaccination against influenza is
recommended for all persons aged 6 months or older.
Healthy persons , non pregnant (2-49 y) with no high-risk medical conditions can receive (LAIV) or IIV.
Health care personnel, immunocompromised and pregnant should receive IIV rather than LAIV.
![Page 18: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/18.jpg)
![Page 19: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/19.jpg)
![Page 20: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/20.jpg)
Pneumococcal Vaccine
![Page 21: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/21.jpg)
clinical form of pneumococcal disease
* Acute otitis media** including empyema
Invasive
Non-invasive
1. WHO. Acute Respiratory Infections (Update September 2009). 2. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine Preventable Diseases. The Pink Book. 11th Edition. May 2009.
![Page 22: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/22.jpg)
![Page 23: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/23.jpg)
![Page 24: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/24.jpg)
29
• The US Advisory Committee on Immunization Practise (ACIP) recommends vaccination of:− All adults aged 65 years and over
− Adults aged 19-64 years with the following underlying medical conditions:
ACIP risk groups for pneumococcal infection
1- Immunocompetent persons Chronic heart disease Chronic lung disease Diabetes mellitus Cerebrospinal fluid leaks Cochlear implant Chronic liver disease
Cigarette smoking2- Functional or anatomic asplenia
Sickle cell disease Splenectomy congenital or acquired asplenia
3-Immunocompromised persons
Congenital or acquired (HIV) immunodeficiet
C R F & Nephrotic Leukaemias & Lymphomas Generalised malignancy Diseases treated with
immunosuppression( steroids >1 m or Biologics
Solid organ transplantation
(ACIP) recommends vaccination of: All adults aged 65 years and over Adults aged 19-64 years with the following underlying medical conditions:
1. Centers for Disease Control and Prevention. MMWR. Prevention of Pneumococcal Disease. ACIP Recommendations 2010;59:1102–1106.
![Page 25: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/25.jpg)
Pneumococcal VaccineAdults aged 19 years or older with underlying medical conditions should receive a single dose of PCV13 followed 8 weeks later by a dose of PPSV23
![Page 26: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/26.jpg)
Prevenar 13 (PCV13):
23F19F18C149V6B4
19A7F6A531
1.Prevenar EPAR. 2. Prevenar 13 Summary of Product Characteristics March 2012. 3. Centers for Disease Control and Prevention. Update: Haemophilus influenzae type b vaccine. MMWR. 1989;38:14. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001330.html. Accessed May 24, 2011.
Using CRM197 , the same carrier protein as Prevenar 1,2, with more than 20 years of experience in vaccines 3
![Page 27: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/27.jpg)
![Page 28: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/28.jpg)
![Page 29: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/29.jpg)
Herpes Zoster
![Page 30: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/30.jpg)
SHINGLES(HERPES ZOSTER)
![Page 31: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/31.jpg)
![Page 32: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/32.jpg)
![Page 33: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/33.jpg)
Effect Of Herpes Zoster Vaccine
![Page 34: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/34.jpg)
Herpes Zoster / ShinglesLive attenuated VZV in amount 14 times
greater in minimum potency than varicella vaccine ,to elicit a significant increase in the CMI to VZV among older adults
Since 2006, the ACIP/CDC recommends to vaccinate all people > 60 y regardless of history of shingles.
CDC has recommendation and both Zoster & Pneumococcal vaccines can be administered at the same visit if indicated.
![Page 35: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/35.jpg)
Only single dose.Also persons with
chronic medical conditions Can be vaccinated
Herpes zoster vaccination
![Page 36: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/36.jpg)
H zoster use in immunocompromised
![Page 37: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/37.jpg)
H ZOSTER for immunocompromised Retrospective study of 463,541 with age >60 y
with 1 of the following autoimmune diseases: rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, or inflammatory bowel disease.
19,000 of received zoster vaccine, of them 633 patients exposed to biologics (551 anti TNF) .
Incidence of HZ within 42 days post vaccination and follow up period of 2 years.
![Page 38: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/38.jpg)
Demographic Data
![Page 39: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/39.jpg)
immunosuppressive Treatment
![Page 40: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/40.jpg)
H ZOSTER for immunocompromised None of these patients on biologics
developed varicella or HZ in 42 days
Decrease incidence of H zoster by 39 % in vaccinated group in 2 years
ACIP recommended that persons > 60 to receive zoster vaccine with or without immunocomromised conditions .
![Page 41: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/41.jpg)
![Page 42: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/42.jpg)
Human Papilloma Virus
![Page 43: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/43.jpg)
0–1 Year 0–5 Years 1–20 Years
Invasive Cervical Cancer
Cleared HPV Infection (~80%)
1. Pinto AP, Crum CP. Clin Obstet Gynecol. 2000;43:352–362. cervical intraepithelial neoplasia (CIN).
CIN 1
InitialHPV
Infection
ContinuingInfection
CIN 2/3
Natural History of HPV Infection and Potential Progression to Cervical Cancer
![Page 44: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/44.jpg)
![Page 45: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/45.jpg)
Recurrent Respiratory Papillomatosis
![Page 46: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/46.jpg)
![Page 47: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/47.jpg)
Routine immunization of females at 11-12 years
Vaccination of females up to age 26
3 Dose 0, 1, 6 months
Human Papilloma virus Vaccine- Recommendations Age & Dose
![Page 48: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/48.jpg)
![Page 49: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/49.jpg)
![Page 50: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/50.jpg)
Meningoccal Disease
![Page 51: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/51.jpg)
Meningococcal vaccine should be administered to persons with the following indications:
1-Medical: A 2-dose series of meningococcal conjugate vaccine (8 w apart ) is recommended for adults with anatomic or functional asplenia, or persistent complement component deficiencies.
2-Adults with HIV infection : to receive a routine 2-doses The 2 doses should be administered at 0 and 2 months
Meningococcal vaccination
![Page 52: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/52.jpg)
Administer a single dose to1- Microbiologists routinely exposed to N
meningitidis2- Military recruits, 3- Those who travel to or live in countries in which
meningococcal disease is hyperendemic or epidemic.
Revaccination with MCV4 every 5 years is recommended for adults who remain at increased risk for
Meningococcal vaccination
![Page 53: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/53.jpg)
![Page 54: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/54.jpg)
Tetanus, diphtheria & Acellular pertussis (Tdap)
![Page 55: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/55.jpg)
Tetanus, Diphtheria & Pertussis (Tdap), cont
Adults are recognized as a reservoir of transmission of Pertussis to a susceptible infants at greatest risk of complications
Updated schedule for Tdap adults 19-64 y to receive a one dose of Tdap
followed Td booster every 10 years
Pregnant women: Tdap during 3rd trimester of every pregnancy
![Page 56: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/56.jpg)
T dap
![Page 57: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/57.jpg)
Varicella
![Page 58: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/58.jpg)
All adults without evidence of immunity to varicella should receive 2 doses (1 month apart )
Evidence of immunity to varicella in adults includes any of the following:
1- Documentation of 2 doses of varicella vaccine at least 4 weeks apart
2-History of varicella diagnosed by healthcare provider
Varicella vaccination
![Page 59: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/59.jpg)
![Page 60: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/60.jpg)
![Page 61: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/61.jpg)
Hepatitis vaccination
![Page 62: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/62.jpg)
Vaccinate any person seeking protection from hepatitis
A virus (HAV) or persons with any of the following
— Persons with chronic liver disease or who is receiveing clotting factor concentrates.
— Persons who use injection or non injection illicit drugs.
— Persons traveling to or working in countries that have high endemicity of hepatitis A
Hepatitis A vaccination
![Page 63: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/63.jpg)
Hepatitis A vaccination2 doses at 0 and 6 months (Havrix )
Or Twinrix (Hepatitis A+B)0-1-6
Or Twinrix a 4-dose schedule (days 0, 7, and 21 ) followed by a booster dose a 12 month .
![Page 64: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/64.jpg)
![Page 65: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/65.jpg)
Hemodialysis and Hepatitis B Vaccination For hemodialysis or immunocompromised 2 doses of 20 μg/mL (Engerix-B) administered simultaneously on a 4-dose schedule( 0, 1, 2, and 6 months)
![Page 66: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/66.jpg)
![Page 67: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/67.jpg)
![Page 68: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/68.jpg)
Measles Mumps Rubella
![Page 69: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/69.jpg)
Women of childbearing age rubella immunity should be checked . If no immunity, and not pregnant should be vaccinated.
Pregnant women with no immunity should receive MMR vaccine upon completion or termination of pregnancy and before discharge from the hospital
Rubella component
![Page 70: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/70.jpg)
![Page 71: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/71.jpg)
Conclusion Our immunocompromised patients should vaccinated with Influenza , Pneumococcal , H Zoster ,Tdap , Hepatitis , Human Papilloma virus
![Page 72: Adult Vaccine 2013 final](https://reader036.fdocuments.us/reader036/viewer/2022062702/554b4475b4c9054b5e8b4c29/html5/thumbnails/72.jpg)